CTOs on the Move

myMatrixx

www.mymatrixx.com

 
myMatrixx is a full-service pharmacy benefit management (PBM) and ancillary services company focused on workers’ compensation. By combining advanced technology and proactive clinical management throughout the claims process, myMatrixx delivers a Fast, Simple, Effective solution with proven Results. Founded in 2001 by Steven MacDonald, an industry veteran in workers’ compensation, myMatrixx began as a pharmacy benefit manager. Today services include a corporately-owned and operated mail service pharmacy with compounding, ancillary services and DME, and proactive clinical programs. With a focus on workers’ compensation, myMatrixx serves self-insured employers, third party administrators, managed care companies, as well as workers’ compensation and auto insurance ...
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.mymatrixx.com
  • 5706 Benjamin Center Dr Ste 103
    Tampa, FL USA 33634
  • Phone: 813.425.9655

Executives

Name Title Contact Details

Similar Companies

Halcyon Rehabilitation

Halcyon Rehabilitation enhances the quality of life in the community we service through top tier Physical Therapy, Occupational Therapy and Speech Language Pathology focused on long term care facilities. Our population focused programs allow us to assi...

WESKetch Architecture

WESKetch Architecture is a Millington, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Critical Outcome Technologies

Critical Outcome Technologies Inc. is a London, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SAB Biotherapeutics

SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine™ herds that produce fully-human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer. SAB`s versatile DiversitAb™ platform is appliable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB is currently advancing multiple clinical programs and has a number of collaborations with the US government and global pharmaceutical companies.